Evidence map›Paper›PMID 40903703›Full record

ReviewInfectious diseases and therapy2025

A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?

Maytham Hussein, James Barclay, Mark Baker, Yuezhou Wu, Varsha J Thombare, Nitin Patil, Ananya B Murthy, Rajnikant Sharma, Gauri G Rao, Mark A T Blaskovich and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. The global epidemiology of MRSA.JAC-antimicrobial resistance · 2026
    Review
  4. Article
  5. ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maytham HusseinMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia.
James BarclayMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia.
Mark BakerDiscipline of Biological Sciences, Priority Research Centre in Reproductive Biology, Faculty of Science and IT, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia.
Yuezhou WuMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia.
Varsha J ThombareResearch Triangle Institute, Durham, NC, 27709, USA.
Nitin PatilResearch Triangle Institute, Durham, NC, 27709, USA.
Ananya B MurthyUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Rajnikant SharmaTitus Family Department of Clinical Practice, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, 1985 Zonal Avenue, PSC 512 E, Los Angeles, CA, 90089, USA.
Gauri G RaoUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Mark A T BlaskovichCentre for Superbug Solutions and ARC Training Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance, Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, 4072, Australia.
Jian LiMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC, 3800, Australia.
Tony VelkovMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia. tony.velkov@monash.edu.

Funding

Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’R01AI170889 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MALONEY, SARA ELIZABETH, RAO, GAURI G · 2022 to 2025
$3.8M
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approachR01AI146241 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAYE, KEITH S, RAO, GAURI G · 2019 to 2023
$3.0M
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases R01AI146241Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases R01AI170889NIAID NIH HHS R01 AI146241NIAID NIH HHS R01 AI170889
6 · The paper itself

Abstract

The clinical landscape of Gram-positive infections has been reshaped with the introduction of long-acting lipoglycopeptides, particularly dalbavancin and oritavancin. Both agents share broad-spectrum activity against multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant strains, yet differ markedly in pharmacokinetics, pharmacodynamics, resistance profiles, and clinical adoption. This review presents a comprehensive comparative analysis of their structural innovations, distinct pharmacokinetic and pharmacodynamic characteristics, and dual mechanisms of action, supported by minimum inhibitory concentration data across key pathogens. Despite belonging to the same antimicrobial class, these agents exhibit important differences in real-world applications and clinical integration. We highlight real-world evidence supporting off-label use in osteomyelitis, endocarditis, and bloodstream infections, where traditional therapies fall short. Furthermore, we explore resistance development, drug-drug interaction profiles, and outpatient utility, providing actionable insights for optimizing treatment strategies. These findings underscore the need for tailored clinical integration of dalbavancin and oritavancin and spotlight their potential roles in future antimicrobial stewardship frameworks.

Indexed as

Antimicrobial resistanceAntimicrobial stewardshipDalbavancinMethicillin-resistant Staphylococcus aureusOff-label useOritavancinPharmacokinetics

Identifiers

PMID40903703
PMCPMC12480267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.